ClearOne to merge with Cortigent, pivoting to neurotech under new Nasdaq ticker
What's the deal? ClearOneDealroom has a profile for this one. Try Dealroom → signed a definitive merger agreement on July 1, 2026, to combine with CortigentDealroom has a profile for this one. Try Dealroom →, a neurotechnology firm owned by Vivani MedicalDealroom has a profile for this one. Try Dealroom →. The company announced the transaction on July 2, and plans to rename itself Cortigent Holdings, Inc.Dealroom has a profile for this one. Try Dealroom →, trading on Nasdaq under the ticker CRGT.
How it works: A ClearOne subsidiary will merge with Cortigent, making it a wholly owned subsidiary. But Vivani Medical is set to receive 12.5 million ClearOne shares and own roughly 59.4% to 67.5% of the combined company. Existing ClearOne shareholders would hold about 12.7% to 14.4% — making this effectively a reverse merger.
Who's involved? ClearOne historically built audio and video conferencing technology for meeting rooms, classrooms, and corporate settings. Cortigent develops medical devices that use electrical stimulation to interact with the brain, aiming to restore lost functions from neurological conditions.
Why now? ClearOne overhauled its strategy in 2025, selling substantial operating assets and intellectual property to BiampDealroom has a profile for this one. Try Dealroom → in October 2025. That sale left much of its traditional conferencing business behind, and the company began exploring strategic alternatives.
What's the endgame? Cortigent's lead program is the Orion Visual Cortical Prosthesis System, designed to give visual perception to people with profound blindness. It is also developing a Stroke Recovery System to help restore arm and hand movement in stroke patients.
What could go wrong? The deal, expected to close in Q3 2026, is subject to ClearOne shareholder approval, planned financing of $10 million to $15 million, Nasdaq listing requirements, and other customary conditions. No fixed purchase price was disclosed.
The signal: The transaction marks a full transformation for ClearOne, turning an audio-video company into a neurotechnology and medical-device business, and offering Cortigent a public-market route without a traditional IPO.
Read more: BizExtract
Image credit: jurvetson
